Respiri's (ASX:RSH) patient programs showed a "significant" reduction in hospitalizations and emergency room visits, accelerating discussions with new and existing clients, according to a Friday filing with the Australian bourse.
The programs registered a 56% decline in rehospitalizations and a 47% drop in emergency room visits.
The medical devices company is in advanced contract discussions with new potential clients as it increases revenues for existing partner Ceras' clients by 51%, to $74 from around $49 per patient per month, and increased the number of monthly reimbursed services to patients to 1.4 from around 1, the filing stated.
The company's shares jumped 5% in recent Monday trade.
Price (AUD): $0.04, Change: $+0.002, Percent Change: +5.00%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.